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Background
The Alliance for Microbicide Development, AIDS Vaccine
Advocacy Coalition, International AIDS Vaccine Initiative
and UNAIDS have since 2004 employed their jointly-
developed, comprehensive methodology to estimate
financial investments and trends related to HIV vaccine
research, development and advocacy and levels of politi-
cal commitment.
Methods
Investment data were collected on product development,
clinical trials and trial preparation, community education,
and policy advocacy efforts, to estimate 2008 funding for
preventive HIV vaccine R&D.
Results
This presentation will provide estimates of total 2008
funding levels by public, commercial and philanthropic
sectors, an overview of trends from 2000–2008, and addi-
tional information on how funds for HIV vaccine R&D
were spent in 2008. A key highlight is that in 2008, despite
the beginnings of a global recession, the HIV vaccine
research public and philanthropic sector funding was sim-
ilar to 2007. In contrast, commercial investment in HIV
vaccines in 2008 declined significantly as compared to the
previous year.
Conclusion
Data on 2008 investment indicate that the onset of the
current global financial climate has had a limited impact
on funding for HIV vaccines. The full effect of the reces-
sion is not likely to be seen until 2009 or beyond due to
funding cycles, but public sector and philanthropic fund-
ing remained stable despite the economic climate and the
disappointing results from the Step and Phambili trials.
Reductions in commercial investment occurred reflecting
completion of the Step trial and contractions in the phar-
maceutical/biotech sector generally. Key issues such as the
quality, sustainability and predictability of funding can
also impact HIV vaccine R&D. Substantial investments are
still needed to strengthen basic research into immunol-
ogy, explore new HIV vaccine designs, bring novel HIV
vaccine candidates into the pipeline and fund clinical tri-
als to test the safety, immunogenicity and efficacy of new
products.
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